Trade Biodesix, Inc. - BDSX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0564 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 1.9169 |
Open* | 1.9269 |
1-Year Change* | -47.78% |
Day's Range* | 1.9269 - 1.9968 |
52 wk Range | 0.96-4.04 |
Average Volume (10 days) | 139.05K |
Average Volume (3 months) | 4.06M |
Market Cap | 138.35M |
P/E Ratio | -100.00K |
Shares Outstanding | 71.69M |
Revenue | 35.83M |
EPS | -1.73 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Mar 13, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 6, 2023 | 1.9768 | 0.0499 | 2.59% | 1.9269 | 2.0168 | 1.9269 |
Feb 3, 2023 | 1.9169 | -0.1498 | -7.25% | 2.0667 | 2.1067 | 1.7871 |
Feb 2, 2023 | 2.1466 | -0.2296 | -9.66% | 2.3762 | 2.4262 | 2.1266 |
Feb 1, 2023 | 2.3263 | -0.1099 | -4.51% | 2.4362 | 2.4362 | 2.2663 |
Jan 31, 2023 | 2.3862 | -0.0399 | -1.64% | 2.4261 | 2.5061 | 2.3262 |
Jan 30, 2023 | 2.3862 | -0.0299 | -1.24% | 2.4161 | 2.4561 | 2.2663 |
Jan 27, 2023 | 2.4661 | 0.1598 | 6.93% | 2.3063 | 2.4961 | 2.2963 |
Jan 26, 2023 | 2.3163 | -0.0200 | -0.86% | 2.3363 | 2.4961 | 2.2763 |
Jan 25, 2023 | 2.3563 | -0.0399 | -1.67% | 2.3962 | 2.4561 | 2.2663 |
Jan 24, 2023 | 2.3463 | 0.0200 | 0.86% | 2.3263 | 2.3962 | 2.3063 |
Jan 23, 2023 | 2.3263 | 0.0100 | 0.43% | 2.3163 | 2.3962 | 2.2264 |
Jan 20, 2023 | 2.3862 | 0.1498 | 6.70% | 2.2364 | 2.3862 | 2.1965 |
Jan 19, 2023 | 2.2165 | -0.0199 | -0.89% | 2.2364 | 2.2365 | 2.1765 |
Jan 18, 2023 | 2.2464 | -0.1697 | -7.02% | 2.4161 | 2.4162 | 2.1665 |
Jan 17, 2023 | 2.3862 | -0.0799 | -3.24% | 2.4661 | 2.4861 | 2.3462 |
Jan 13, 2023 | 2.4761 | 0.1498 | 6.44% | 2.3263 | 2.4861 | 2.2464 |
Jan 12, 2023 | 2.4661 | 0.0599 | 2.49% | 2.4062 | 2.4661 | 2.3262 |
Jan 11, 2023 | 2.3862 | -0.0100 | -0.42% | 2.3962 | 2.4561 | 2.2464 |
Jan 10, 2023 | 2.3563 | -0.0599 | -2.48% | 2.4162 | 2.4162 | 2.1466 |
Jan 9, 2023 | 2.3463 | 0.1698 | 7.80% | 2.1765 | 2.3862 | 2.1665 |
Biodesix, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|
Total revenue | 20.432 | 24.552 | 45.557 | 54.506 |
Revenue | 20.432 | 24.552 | 45.557 | 54.506 |
Cost of Revenue, Total | 4.406 | 6.074 | 21.998 | 30.518 |
Gross Profit | 16.026 | 18.478 | 23.559 | 23.988 |
Total Operating Expense | 44.095 | 51.293 | 68.491 | 93.148 |
Selling/General/Admin. Expenses, Total | 25.899 | 30.637 | 32.328 | 47.958 |
Research & Development | 8.188 | 10.468 | 10.818 | 12.789 |
Unusual Expense (Income) | 5.602 | 4.114 | 0.818 | -0.676 |
Operating Income | -23.663 | -26.741 | -22.934 | -38.642 |
Interest Income (Expense), Net Non-Operating | -2.892 | -2.953 | -7.586 | -4.508 |
Other, Net | 0.389 | -1.032 | -0.83 | -0.009 |
Net Income Before Taxes | -26.166 | -30.726 | -31.35 | -43.159 |
Net Income After Taxes | -26.166 | -30.726 | -31.35 | -43.159 |
Net Income Before Extra. Items | -26.166 | -30.726 | -31.35 | -43.159 |
Net Income | -26.166 | -30.726 | -31.35 | -43.159 |
Income Available to Common Excl. Extra. Items | -26.166 | -30.726 | -31.35 | -43.159 |
Income Available to Common Incl. Extra. Items | -26.166 | -30.726 | -31.35 | -43.159 |
Diluted Net Income | -26.166 | -30.726 | -31.35 | -43.159 |
Diluted Weighted Average Shares | 26.2541 | 26.2541 | 26.5615 | 27.365 |
Diluted EPS Excluding Extraordinary Items | -0.99665 | -1.17033 | -1.18028 | -1.57716 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
Diluted Normalized EPS | -0.78327 | -1.01363 | -1.14948 | -1.60186 |
Depreciation / Amortization | 2.529 | 2.559 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 28.866 | 11.885 | 6.531 | 7.224 | 6.548 |
Revenue | 28.866 | 11.885 | 6.531 | 7.224 | 6.548 |
Cost of Revenue, Total | 18.218 | 7.085 | 2.722 | 2.493 | 3.235 |
Gross Profit | 10.648 | 4.8 | 3.809 | 4.731 | 3.313 |
Total Operating Expense | 35.177 | 22.472 | 16.499 | 19 | 21.009 |
Selling/General/Admin. Expenses, Total | 11.927 | 11.425 | 13.607 | 13.558 | 14.487 |
Research & Development | 3.321 | 3.323 | 3.293 | 2.852 | 3.206 |
Unusual Expense (Income) | 1.711 | 0.639 | -3.123 | 0.097 | 0.081 |
Operating Income | -6.311 | -10.587 | -9.968 | -11.776 | -14.461 |
Interest Income (Expense), Net Non-Operating | -0.651 | -0.815 | -1.546 | -1.496 | -1.137 |
Other, Net | 0.001 | 0 | 0 | -0.01 | 0.012 |
Net Income Before Taxes | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
Net Income After Taxes | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
Net Income Before Extra. Items | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
Net Income | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
Income Available to Common Excl. Extra. Items | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
Income Available to Common Incl. Extra. Items | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
Diluted Net Income | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
Diluted Weighted Average Shares | 26.604 | 27.73 | 28.051 | 27.059 | 31.07 |
Diluted EPS Excluding Extraordinary Items | -0.26165 | -0.41118 | -0.41047 | -0.49085 | -0.50164 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.19734 | -0.38814 | -0.5218 | -0.48727 | -0.49903 |
- Annual
- Quarterly
2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|
Total Current Assets | 9.913 | 12.7 | 86.14 | 43.613 |
Cash and Short Term Investments | 5.914 | 5.286 | 62.126 | 32.712 |
Cash & Equivalents | 5.914 | 5.286 | 62.126 | 32.712 |
Total Receivables, Net | 1.892 | 5.292 | 15.304 | 3.656 |
Accounts Receivable - Trade, Net | 1.892 | 5.292 | 15.304 | 3.656 |
Other Current Assets, Total | 2.107 | 2.122 | 8.71 | 7.245 |
Total Assets | 39.057 | 41.633 | 121.07 | 76.097 |
Property/Plant/Equipment, Total - Net | 1.388 | 2.12 | 3.178 | 4.179 |
Property/Plant/Equipment, Total - Gross | 6.956 | 8.506 | 9.902 | 10.928 |
Accumulated Depreciation, Total | -5.568 | -6.386 | -6.724 | -6.749 |
Goodwill, Net | 10.804 | 11.631 | 15.031 | 15.031 |
Intangibles, Net | 16.852 | 15.092 | 13.26 | 11.617 |
Other Long Term Assets, Total | 0.1 | 0.09 | 3.461 | 1.657 |
Total Current Liabilities | 4.468 | 22.6 | 32.125 | 28.96 |
Accounts Payable | 0.886 | 1.717 | 8.964 | 1.662 |
Accrued Expenses | 1.568 | 1.899 | 4.69 | 4.899 |
Notes Payable/Short Term Debt | 0 | 12.045 | 0 | 0 |
Other Current Liabilities, Total | 2.014 | 6.939 | 6.631 | 22.38 |
Total Liabilities | 53.125 | 76.213 | 79.904 | 56.37 |
Total Long Term Debt | 23.099 | 23.812 | 15.926 | 9.993 |
Long Term Debt | 23.099 | 23.812 | 15.926 | 9.993 |
Other Liabilities, Total | 25.558 | 29.801 | 31.853 | 17.417 |
Total Equity | -14.068 | -34.58 | 41.166 | 19.727 |
Redeemable Preferred Stock | 183.962 | 193.959 | 0 | 0 |
Common Stock | 0.001 | 0.001 | 0.027 | 0.031 |
Additional Paid-In Capital | 2.107 | 2.324 | 299.953 | 321.669 |
Retained Earnings (Accumulated Deficit) | -200.138 | -230.864 | -258.814 | -301.973 |
Total Liabilities & Shareholders’ Equity | 39.057 | 41.633 | 121.07 | 76.097 |
Total Common Shares Outstanding | 26.2541 | 26.2541 | 26.5615 | 30.7896 |
Current Port. of LT Debt/Capital Leases | 0 | 11.84 | 0.019 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 81.244 | 68.45 | 56.445 | 43.613 | 27.233 |
Cash and Short Term Investments | 55.329 | 56.349 | 47.913 | 32.712 | 16.427 |
Cash & Equivalents | 55.329 | 56.349 | 47.913 | 32.712 | 16.427 |
Total Receivables, Net | 18.367 | 5.281 | 2.784 | 3.656 | 3.774 |
Accounts Receivable - Trade, Net | 18.367 | 5.281 | 2.784 | 3.656 | 3.774 |
Other Current Assets, Total | 7.548 | 6.82 | 5.748 | 7.245 | 7.032 |
Total Assets | 115.486 | 101.804 | 89.997 | 76.097 | 61.651 |
Property/Plant/Equipment, Total - Net | 3.387 | 3.378 | 4.432 | 4.179 | 6.247 |
Property/Plant/Equipment, Total - Gross | 10.369 | 10.471 | 11.827 | 10.928 | 13.409 |
Accumulated Depreciation, Total | -6.982 | -7.093 | -7.395 | -6.749 | -7.162 |
Goodwill, Net | 15.031 | 15.031 | 15.031 | 15.031 | 15.031 |
Intangibles, Net | 12.821 | 12.4 | 11.992 | 11.617 | 11.131 |
Other Long Term Assets, Total | 3.003 | 2.545 | 2.097 | 1.657 | 2.009 |
Total Current Liabilities | 16.124 | 21.272 | 22.787 | 28.96 | 29.811 |
Accounts Payable | 3.747 | 1.16 | 1.6 | 1.662 | 2.12 |
Accrued Expenses | 2.622 | 2.959 | 3.533 | 4.899 | 4.597 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 2.707 | 3.106 | 0.02 | 0.019 | 0.051 |
Other Current Liabilities, Total | 7.048 | 14.047 | 17.634 | 22.38 | 23.043 |
Total Liabilities | 79.054 | 76.031 | 73.964 | 56.37 | 53.87 |
Total Long Term Debt | 30.328 | 29.955 | 29.975 | 9.993 | 10.055 |
Long Term Debt | 30.328 | 29.955 | 29.975 | 9.993 | 10.055 |
Other Liabilities, Total | 32.602 | 24.804 | 21.202 | 17.417 | 14.004 |
Total Equity | 36.432 | 25.773 | 16.033 | 19.727 | 7.781 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
Common Stock | 0.027 | 0.027 | 0.027 | 0.031 | 0.032 |
Additional Paid-In Capital | 302.18 | 302.923 | 304.697 | 321.669 | 325.308 |
Retained Earnings (Accumulated Deficit) | -265.775 | -277.177 | -288.691 | -301.973 | -317.559 |
Total Liabilities & Shareholders’ Equity | 115.486 | 101.804 | 89.997 | 76.097 | 61.651 |
Total Common Shares Outstanding | 26.7854 | 26.9489 | 27.0201 | 30.7896 | 31.8893 |
- Annual
- Quarterly
2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|
Net income/Starting Line | -26.166 | -30.726 | -31.35 | -43.159 |
Cash From Operating Activities | -17.677 | -21.726 | -21.366 | -28.223 |
Cash From Operating Activities | 1.74 | 2.793 | 2.903 | 3.178 |
Non-Cash Items | 6.496 | 7.852 | 11.882 | 7.167 |
Changes in Working Capital | 0.253 | -1.645 | -4.801 | 4.591 |
Cash From Investing Activities | -0.617 | -1.872 | -2.927 | -2.547 |
Capital Expenditures | -0.617 | -1.416 | -2.177 | -2.547 |
Other Investing Cash Flow Items, Total | 0 | -0.456 | -0.75 | 0 |
Cash From Financing Activities | 19.032 | 22.972 | 81.131 | 1.262 |
Financing Cash Flow Items | -0.283 | -0.119 | -8.249 | -0.5 |
Issuance (Retirement) of Stock, Net | 8.55 | 10.047 | 73.34 | 17.112 |
Issuance (Retirement) of Debt, Net | 10.765 | 13.044 | 16.04 | -15.35 |
Net Change in Cash | 0.738 | -0.626 | 56.838 | -29.508 |
Cash Interest Paid | 1.844 | 1.676 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -6.961 | -18.363 | -29.877 | -43.159 | -15.586 |
Cash From Operating Activities | -11.326 | -10.236 | -18.026 | -28.223 | -13.099 |
Cash From Operating Activities | 0.746 | 1.523 | 2.323 | 3.178 | 0.908 |
Non-Cash Items | 3.721 | 5.336 | 4.704 | 7.167 | 2.674 |
Changes in Working Capital | -8.832 | 1.268 | 4.824 | 4.591 | -1.095 |
Cash From Investing Activities | -0.516 | -0.864 | -1.906 | -2.547 | -0.352 |
Capital Expenditures | -0.516 | -0.864 | -1.906 | -2.547 | -0.352 |
Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
Cash From Financing Activities | 4.951 | 5.229 | 5.625 | 1.262 | -2.834 |
Financing Cash Flow Items | -0.108 | -0.109 | 0.232 | -0.5 | -4.6 |
Issuance (Retirement) of Stock, Net | 0.475 | 0.679 | 0.739 | 17.112 | 1.674 |
Issuance (Retirement) of Debt, Net | 4.584 | 4.659 | 4.654 | -15.35 | 0.092 |
Net Change in Cash | -6.891 | -5.871 | -14.307 | -29.508 | -16.285 |
Cash Interest Paid | 0.223 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Schuler (Jack W) | Individual Investor | 27.8328 | 19952112 | 8695652 | 2022-11-21 | LOW |
Kennedy (Lawrence T Jr.) | Individual Investor | 20.684 | 14827404 | 0 | 2023-01-03 | MED |
Patience (John) | Individual Investor | 9.7923 | 7019695 | 1739130 | 2022-11-21 | LOW |
Birchview Capital, LP | Investment Advisor | 7.0302 | 5039633 | 2884624 | 2022-12-31 | LOW |
Cawthorn (Robert E) | Individual Investor | 5.0948 | 3652220 | 1723341 | 2022-11-21 | LOW |
Strobeck (Matthew W) | Individual Investor | 4.052 | 2904668 | 1304345 | 2022-11-21 | LOW |
Industrial Development Funding LLC | Corporation | 2.6454 | 1896374 | 0 | 2022-03-01 | LOW |
Wells Fargo Advisors | Research Firm | 1.0724 | 768725 | 221413 | 2022-09-30 | LOW |
Essex Investment Management Company, LLC | Investment Advisor/Hedge Fund | 0.5273 | 377994 | -29 | 2022-12-31 | LOW |
Life Sciences Alternative Financing, L.L.C. | Corporation | 0.4102 | 294053 | 0 | 2022-03-01 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.3343 | 239656 | 59660 | 2022-09-30 | LOW |
Cannell & Co. | Investment Advisor | 0.2868 | 205605 | 0 | 2022-12-31 | LOW |
Hutton Scott | Individual Investor | 0.2389 | 171227 | 96218 | 2022-11-21 | LOW |
Massarany (Hany) | Individual Investor | 0.1924 | 137934 | 130434 | 2022-11-21 | HIGH |
Endurant Capital Management LP | Hedge Fund | 0.1815 | 130136 | -617 | 2022-09-30 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.1731 | 124070 | 27282 | 2022-09-30 | LOW |
Millennium Management LLC | Hedge Fund | 0.1647 | 118048 | 728 | 2022-09-30 | HIGH |
Bridgeway Capital Management, LLC | Investment Advisor | 0.1395 | 100000 | 50000 | 2022-09-30 | LOW |
Pestano (Gary Anthony) | Individual Investor | 0.1294 | 92732 | 3474 | 2022-11-10 | |
Cowie (Robin Harper) | Individual Investor | 0.1282 | 91920 | 25383 | 2022-11-21 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Biodesix, Inc. Company profile
About Biodesix Inc
Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Biodesix Inc revenues increased 20% to $54.5M. Net loss increased 38% to $43.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales, marketing, general and administ increase of 49% to $43.6M (expense), Research and development - Balancing v increase of 19% to $12.2M (expense).
Industry: | Medical & Diagnostic Laboratories |
Suite 100
2970 Wilderness Place
BOULDER
COLORADO 80301
US
Income Statement
- Annual
- Quarterly
News

Japanese Yen Outlook: USD/JPY Edging Towards YTD Peak on BoJ Dove and US Yields
Japanese Yen underperforms with BoJ dove touted to be Governor Kuroda successor.
14:36, 6 February 2023
S&P 500 & DAX 40 Forecast for the Week Ahead
S&P 500 builds higher after Fed meeting, DAX 40 runs into resistance
16:30, 3 February 2023
FX Weekly Outlook: USD, GBP/USD, USD/JPY Analysis
USD, GBP/USD, USD/JPY forecasts for the week ahead.
15:56, 3 February 2023
GBP/USD drops below 1.23 as BOE comments suggest possible end of rate hikes
Despite increasing rates by 50bps at their February meeting, the messaging from the BOE suggests a dovish tilt an the possible end of rate hikes.
15:37, 2 February 2023
Gold latest: XAU/USD rallies on Fed meeting as traders eye Friday’s jobs data
Gold buyers take advantage of risk on sentiment as they eye Friday's NFP data to assess the likelihood of a soft landing
11:48, 2 February 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com